[Lumacaftor/ivacaftor (cystic fibrosis, homozygous F508del mutation in the CFTR gene, 2-5 years) - Benefit assessment according to §35a Social Code Book V (expiry of the limitation period)]

Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen
Record ID 32018004027
Original Title: Lumacaftor/Ivacaftor (zystische Fibrose, 2 bis 5 Jahre, F508del-Mutation, homozygot)
Project Status: Completed
Year Published: 2021
English language abstract: There is no English language summary available
Publication Type: Full HTA
Country: Germany
MeSH Terms
  • Cystic Fibrosis
  • Child
  • Child, Preschool
  • Aminophenols
  • Quinolones
  • Drug Therapy, Combination
  • Lumacaftor
  • Ivacaftor
  • Cystic Fibrosis
  • Child - Preschool
  • Benefit Assessment
  • NCT03625466
Organisation Name: Institute for Quality and Efficiency in Health Care (IQWiG)
Contact Address: IQWiG, Im Mediapark, 8, DE-50670 Cologne, GERMANY, Tel: +49(0)221-35685, Fax: +49(0)221-356851
Contact Email: berichte@iqwig.de
Copyright: Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.